Nefecon has become the first and only approved treatment in the EU for primary immunoglobulin A nephropathy (IgAN), a rare, progressive kidney disease. The European Medicines Agency said that the medicine “was shown to be effective at lowering the level of excess protein in the urine in patients with IgAN, indicating an improvement in kidney […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!